Angiotensin-converting enzyme inhibitors, antihypertensive drugs and food products
By using 3-(4-hydroxy-3-methoxyphenyl)propionic acid cinnamic acid derivative as an angiotensin converting enzyme inhibitor, the problem of difficulty in inhibiting angiotensin converting enzyme in hypertension is solved, and effective The antihypertensive effect protects the health of the heart and kidneys.
Patent Information
- Application Number
- CN202080068479.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-30
- Filing Date
- 2020-09-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-09-02
AI Technical Summary
The prior art is difficult to effectively inhibit angiotensin converting enzymes, making it difficult to control hypertension and affecting the health of the heart and kidneys.
The compound is prepared by plant extraction or microbial fermentation and compounded in food and beverage using 3-(4-hydroxy-3-methoxyphenyl)propionic acid derivative as an angiotensin converting enzyme inhibitor. to achieve a pressure reduction effect.
This compound has excellent inhibitory effect of angiotensin converting enzyme, which can effectively lower blood pressure, prevent or improve hypertension-related organ damage, such as cardiac insufficiency, myocardial infarction and renal insufficiency.
Smart Images

Figure CN114449906B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to an angiotensin converting enzyme inhibitor, a blood pressure reducing agent and a food and drink product. Background Art
[0002] Hypertension, along with obesity and smoking, is a major risk factor for lifestyle-related diseases. Continuous hypertension may cause: heart failure and myocardial infarction in the heart; kidney damage and renal failure in the kidney; and occlusive and dissecting arterial diseases in the blood vessels. Therefore, there is a strong demand in society to improve hypertension.
[0003] Angiotensin I-Converting Enzyme (ACE) is known as a factor associated with elevated blood pressure. ACE is a dicarboxypeptidase (molecular weight 147 kDa) with zinc as the active center and has two catalytically active domains (C and N domains).
[0004] The C domain of angiotensin converting enzyme catalyzes the reaction of freeing the C-terminal dipeptide of angiotensin I to generate angiotensin II. Angiotensin II causes vascular smooth muscle contraction via receptors (AT1R) present in the vascular wall, thereby causing blood pressure to rise. In addition, angiotensin II promotes the secretion of aldosterone by the adrenal cortex and promotes sodium reabsorption in the kidneys, thereby causing blood pressure to rise (Non-Patent Document 1).
[0005] Therefore, it is thought that blood pressure can be lowered by inhibiting angiotensin converting enzyme. As substances having angiotensin converting enzyme inhibitory activity, decomposition products based on mackerel pyloric spur, which is a fish protein, have been reported (Patent Document 1).
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent Application Publication No. 2013-043839
[0009] Non-patent literature
[0010] Non-patent literature 1: Chemistry and Biology Vol.53.No.4.2015 p.228-235 Summary of the invention
[0011] Technical problem to be solved by the invention
[0012] An object of the present invention is to provide an angiotensin converting enzyme inhibitor, a hypotensive agent, and a food or beverage containing the compound.
[0013] Technical solutions for solving technical problems
[0014] In order to solve the above technical problems, the angiotensin converting enzyme inhibitor and antihypertensive agent of the present invention are characterized in that a compound represented by the following formula (I) is used as an active ingredient. In addition, the angiotensin converting enzyme inhibitor and antihypertensive food and drink of the present invention are characterized in that a compound represented by the following formula (I) is mixed.
[0015]
[0016] Effects of the Invention
[0017] According to the present invention, by making the compound represented by the above-mentioned formula (I) as an effective ingredient, an angiotensin converting enzyme inhibitor and a hypotensive agent with an excellent angiotensin converting enzyme inhibitory effect can be provided. And, by compounding the compound represented by the above-mentioned formula (I), a food and drink suitable for the above-mentioned purposes can be provided. DETAILED DESCRIPTION
[0018] Hereinafter, embodiments of the present invention will be described.
[0019] The ACE inhibitor and antihypertensive agent according to the present embodiment contain a compound represented by the following formula (I) as an active ingredient. In addition, the ACE inhibitor and antihypertensive food and drink according to the present embodiment contain a compound represented by the following formula (I).
[0020]
[0021] The compound represented by the above formula (I) is a cinnamic acid derivative also called 3-(4-hydroxy-3-methoxyphenyl)propionic acid. Hereinafter, in this specification, the compound represented by the above formula (I) may also be referred to as compound (I).
[0022] Compound (I) can be prepared, for example, by isolating and purifying a plant extract containing compound (I). In this case, a plant extract containing such compound (I) can be obtained by a method commonly used in plant extraction. Plants containing compound (I) include, for example, rice, barley, wheat, soybeans, adzuki beans, corn, and the like.
[0023] Compound (I) can also be produced, for example, by fermenting 3-(4-hydroxy-3-methoxyphenyl)propenoic acid or its derivatives, or compositions containing them (e.g., crushed materials or extracts of plants) using a microorganism having a phenolic acid reductase, converting 3-(4-hydroxy-3-methoxyphenyl)propenoic acid into compound (I), and then extracting, isolating, and purifying the resulting fermented product. Examples of compositions containing 3-(4-hydroxy-3-methoxyphenyl)propenoic acid include crushed materials and extracts of plants such as coffee, wheat, corn, tomato, mate, artemisia selengensis, and burdock. In addition, since 3-(4-hydroxy-3-methoxyphenyl)propenoic acid is a constituent component of lignin in woody plants and herbaceous plants, lignin or compositions containing lignin can also be used as fermentation raw materials. On the other hand, examples of microorganisms having phenolic acid reductase include lactic acid bacteria such as Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus crispatus, Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus delbrueckii, Lactobacillus buchneri, Lactobacillus kefiranofaciens, Lactobacillus gallinarum, and Enterococcus faecalis.
[0024] The method for extracting, isolating and purifying compound (I) from the above-mentioned plants or fermented products is not particularly limited and can be carried out according to conventional methods. For example, in the extraction process, after the above-mentioned plants or fermented products as the extraction raw materials are dried, they are directly or crushed using a coarse crusher for extraction based on an extraction solvent. Drying can be carried out by sun drying or using a commonly used dryer. In addition, it can also be used as an extraction raw material after pretreatment such as defatting with a non-polar solvent such as hexane. By performing pretreatments such as defatting, extraction processes based on polar solvents can be efficiently carried out.
[0025] As the extraction solvent, a polar solvent is preferably used, and examples thereof include water and hydrophilic organic solvents. These are preferably used alone or in combination of two or more at room temperature or at a temperature not higher than the boiling point of the solvent.
[0026] Water that can be used as an extraction solvent includes, in addition to pure water, tap water, well water, mineral water, mineral water, hot spring water, spring water, fresh water, etc., water that has been subjected to various treatments. Treatments applied to water include, for example, purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, etc. Therefore, in the present embodiment, water that can be used as an extraction solvent includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, etc.
[0027] Examples of the hydrophilic organic solvent that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propanol, and isopropanol; lower aliphatic ketones such as acetone and methyl ethyl ketone; and polyols having 2 to 5 carbon atoms such as 1,3-butanediol, propylene glycol, and glycerol.
[0028] When a mixture of two or more polar solvents is used as the extraction solvent, the mixing ratio can be adjusted appropriately. For example, when a mixture of water and lower aliphatic alcohol is used as the extraction solvent, the mixing ratio of water to lower aliphatic alcohol is preferably 9:1 to 1:9 (volume ratio), and more preferably 7:3 to 2:8 (volume ratio). In addition, when a mixture of water and lower aliphatic ketone is used, the mixing ratio of water to lower aliphatic ketone is preferably 9:1 to 2:8 (volume ratio), and when a mixture of water and polyol is used, the mixing ratio of water to polyol is preferably 8:2 to 1:9 (volume ratio).
[0029] In the extraction process, there is no particular limitation as long as the soluble components contained in the extraction raw material can be dissolved into the extraction solvent, and it can be carried out according to a conventional method. For example, the extraction raw material can be immersed in an extraction solvent of 5 to 15 times the amount (mass ratio) of the extraction raw material, and after extracting the soluble components at room temperature or under reflux heating, filtering to remove the extraction residue, thereby obtaining an extract. The solvent is distilled off from the obtained extract to obtain a paste-like concentrate, and the concentrate is further dried to obtain a dried product.
[0030] The method of isolating and purifying compound (I) from the extract obtained as above, the concentrate of the extract or the dry product of the extract is not particularly limited and can be carried out according to conventional methods. For example, the extract is dissolved in a developing solvent, added to a column chromatography using a porous material such as silica gel or alumina, a porous resin such as styrene-divinylbenzene copolymer or polymethacrylate, etc., and a method of recovering a component containing compound (I) can be cited. In this case, the developing solvent can be appropriately selected according to the stationary phase used. For example, in the case of separating the extract by normal phase chromatography using silica gel as the stationary phase, the developing solvent is chloroform: methanol = 95: 5, etc. In addition, any organic compound purification means can be used, such as reverse phase silica gel chromatography using ODS; column chromatography using recrystallization, liquid-liquid countercurrent extraction, ion exchange resin, etc. to purify the component containing compound (I) obtained by column chromatography.
[0031] [Angiotensin-converting enzyme inhibitors, antihypertensive agents]
[0032] The compound (I) obtained as described above has an excellent angiotensin converting enzyme inhibitory effect, and thus can be used as an active ingredient of angiotensin converting enzyme inhibitors. In addition, the compound (I) has an excellent hypotensive effect, and thus can also be used as an active ingredient of a hypotensive agent.
[0033] That is, compound (I) can be used to produce an angiotensin converting enzyme inhibitor or a hypotensive agent.
[0034] The angiotensin converting enzyme inhibitor and antihypertensive agent of the present embodiment can be used in a wide range of applications such as pharmaceuticals, quasi-drugs, and cosmetics.
[0035] Here, the hypotensive effect of compound (I) is exerted based on, for example, angiotensin converting enzyme inhibitory effect. However, the hypotensive effect of compound (I) is not limited to the hypotensive effect exerted based on angiotensin converting enzyme inhibitory effect.
[0036] In addition, as the active ingredient of the angiotensin converting enzyme inhibitor and the antihypertensive agent involved in this embodiment, a composition containing compound (I) can also be used instead of the isolated compound (I). Here, the "composition containing compound (I)" in this embodiment includes an extract obtained by using a plant containing compound (I) as an extraction raw material, a fermentation product containing compound (I), and an extract obtained by using the fermentation product as an extraction raw material. In addition, the "extract" includes an extract obtained by extraction treatment, a diluted solution or a concentrated solution of the extract, or a dried product obtained by drying the extract.
[0037] When a composition containing compound (I) is used as the active ingredient of the angiotensin converting enzyme inhibitor and the antihypertensive agent according to the present embodiment, the content of compound (I) in the composition is preferably 0.1% by mass or more, more preferably 5% by mass or more, and particularly preferably 50% by mass or more. By using a substance with improved purity of compound (I) as the active ingredient, angiotensin converting enzyme inhibitor and antihypertensive agent with further excellent effects can be obtained.
[0038] The angiotensin converting enzyme inhibitor and antihypertensive agent of this embodiment may consist of compound (I) alone or a composition containing compound (I), or compound (I) or a composition containing compound (I) may be prepared as a preparation.
[0039] The angiotensin converting enzyme inhibitor and antihypertensive agent of this embodiment can be made into any dosage form such as powder, granule, tablet, liquid, etc. using pharmaceutically acceptable carriers such as dextrin and cyclodextrin and any other auxiliary agents according to conventional methods. At this time, as auxiliary agents, for example, excipients, binders, disintegrants, lubricants, stabilizers, flavoring and olfactory agents, etc. can be used. In addition to being mixed and used in other compositions (for example, skin cosmetics, hair cosmetics, etc.), the angiotensin converting enzyme inhibitor and antihypertensive agent treatment can also be used as ointments, external liquid preparations, patches, etc.
[0040] When the angiotensin converting enzyme inhibitor and the antihypertensive agent of the present embodiment are formulated into a preparation, the content of the compound (I) or the composition containing the compound (I) is not particularly limited and can be appropriately set depending on the intended purpose.
[0041] Furthermore, the angiotensin converting enzyme inhibitor and antihypertensive agent of this embodiment may be mixed with compound (I) or a composition containing compound (I) as necessary, and other natural extracts having angiotensin converting enzyme inhibitory or antihypertensive effects may be used as active ingredients.
[0042] As the method of administering the angiotensin converting enzyme inhibitor and the antihypertensive agent of the present embodiment to the patient, transdermal administration, oral administration, etc. can be listed, and the method suitable for its prevention or treatment, etc. can be appropriately selected according to the type of disease. In addition, the dosage of the angiotensin converting enzyme inhibitor and the antihypertensive agent of the present embodiment can also be appropriately increased or decreased according to the type of disease, severity, individual differences of patients, administration method, administration time, etc.
[0043] The angiotensin converting enzyme inhibitor of this embodiment inhibits the reaction of freeing the C-terminal dipeptide of angiotensin I to generate angiotensin II by the angiotensin converting enzyme inhibitory effect of the compound (I) as an active ingredient. By inhibiting the generation of angiotensin II, the contraction of vascular smooth muscle can be inhibited, thereby lowering blood pressure. In addition to these uses, the angiotensin converting enzyme inhibitor of this embodiment can also be used for all uses that are meaningful for exerting angiotensin converting enzyme inhibitory effect.
[0044] The antihypertensive agent of the present embodiment can inhibit the reaction of freeing the C-terminal dipeptide of angiotensin I to generate angiotensin II by the antihypertensive effect of the compound (I) as an active ingredient. As a result, the antihypertensive agent of the present embodiment can prevent or improve various diseases such as hypertension, heart failure and myocardial infarction associated with it, kidney damage and renal failure in the kidney, and organ damage such as occlusive and dissecting arterial diseases in the blood vessels. However, in addition to these uses, the antihypertensive agent of the present embodiment can also be used for all uses that are meaningful in exerting a antihypertensive effect.
[0045] Furthermore, since the angiotensin converting enzyme inhibitor and antihypertensive agent of the present embodiment have excellent angiotensin converting enzyme inhibitory action or antihypertensive action, they can also be preferably used as reagents for studying the mechanisms of these actions.
[0046] [Angiotensin-converting enzyme inhibitory foods and drinks, blood pressure lowering foods and drinks]
[0047] Compound (I) has excellent angiotensin converting enzyme inhibitory and hypotensive effects and is therefore suitable for mixing with food and beverages. In this case, compound (I) may be mixed directly, or an angiotensin converting enzyme inhibitor or hypotensive agent prepared from compound (I) may be mixed.
[0048] By mixing compound (I) or angiotensin converting enzyme inhibitor or hypotensive agent prepared from compound (I) in food and drink, food and drink suitable for angiotensin converting enzyme inhibition or hypotensive use can be prepared. The above-mentioned effect is easy to exert by imparting it to food and drink, so it is preferred.
[0049] Here, food and drink refers to the possibility of causing harm to people's health is small, in common social life by oral or digestive tract administration and the material of taking, is not limited to the food, medicine, quasi-drug etc. on administrative division.Therefore, " food and drink " in the present embodiment widely includes general food, health food (functional food and drink), health function food (specific health food, nutritional function food), quasi-drug, medicine etc. of oral intake.The food and drink involved in the present embodiment is preferably the food and drink of the preferred effect that can show compound (I) on this food and drink or its packaging, especially preferably health function food (specific health food, functional food, nutritional function food), quasi-drug and medicine.
[0050] In the case of angiotensin converting enzyme inhibitor or hypotensive agent prepared by compound (I) or compound (I) in food and drink, the amount of active ingredient in them can be appropriately changed in consideration of the purpose of use, symptoms, gender, etc., but considering the general intake of food and drink as the object of addition, the extract intake per day for adults is preferably about 1 to 1000 mg. In addition, in the case of food and drink that is a granular, tablet or capsule-shaped food and drink, the amount of compound (I) or compound (I) prepared by compound (I) or hypotensive agent is usually 0.1 to 100% by mass, preferably 5 to 100% by mass, relative to the object of addition.
[0051] The food or beverage of the present embodiment may be a food or beverage obtained by mixing the compound (I) into any food or beverage that does not affect its activity, or may be a nutritional supplement containing the compound (I) as a main ingredient.
[0052] When manufacturing the food and beverage of the present embodiment, for example, sugars such as dextrin and starch; proteins such as gelatin, soy protein, and zein; amino acids such as alanine, glutamine, and isoleucine; polysaccharides such as cellulose and gum arabic; and fats such as soybean oil and medium-chain fatty acid triglycerides can be added to make food and beverage of any shape.
[0053] The food and beverages that can be mixed with compound (I) are not particularly limited. Specific examples thereof include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks (including concentrated original solutions of these beverages and powders for mixing); frozen desserts such as ice cream, ice sorbet, and shaved ice; noodles such as soba noodles, udon noodles, vermicelli noodles, dumpling wrappers, shao mai wrappers, Chinese noodles, and instant noodles; sugar, bubble gum (chewing gum); cakes and pastries such as cakes, candies, chewing gum, chocolate, pressed candies, snack cakes, biscuits, jellies, jams, creams, baked cakes, etc.; fishery-livestock processed foods such as fish cakes, ham, sausages, etc.; dairy products such as processed milk and fermented milk; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, light cream, salad dressing, and oil-processed foods; seasonings such as sauces and dressings; soups, stews, salads, cooked dishes, kimchi; other various forms of health-nutritional supplementary foods; tablets, capsules, drinks, etc. When compound (I) is mixed with these food and beverages, commonly used auxiliary raw materials or additives can be used in combination.
[0054] In addition, the angiotensin converting enzyme inhibitor, antihypertensive agent, angiotensin converting enzyme inhibition food and drink and antihypertensive food and drink of the present embodiment are preferably applicable to humans, but as long as their respective effects can be achieved, they can be applicable to animals other than humans (e.g., mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.).
[0055] Example
[0056] The present invention is specifically described below by showing the test examples, but the present invention is not limited to the following examples. In addition, in the present test examples, compound (I) (manufactured by Tokyo Chemical Industry Co., Ltd., 3-(4-Hydroxy-3-methoxyphenyl)propionic Acid, sample 1) was used as the sample to be tested.
[0057] [Test Example 1] Angiotensin converting enzyme inhibitory effect test of compound (I)
[0058] Compound (I) (Sample 1) was tested for angiotensin converting enzyme inhibitory effect as follows.
[0059] Dispense 50 μL of each of the sample solution (sample 1) and distilled water that have been appropriately dissolved and diluted with distilled water into a test tube (10 mL). Dispense and mix 250 μL of the substrate solution separately. Preheat the test tube in a constant temperature water bath at 37°C for 5 minutes. Add 100 μL of ACE solution to the preheated test tube, stir immediately, and react in a constant temperature water bath at 37°C for 45 minutes. After the reaction is completed, add 3.6 mL of 3% metaphosphoric acid solution and stir thoroughly to complete the reaction. Perform HPLC analysis on the inactivated liquid to determine the free hippuric acid. The ACE inhibition rate (%) is calculated from the hippuric acid peak area and solid amount (concentration, scale weight) obtained by HPLC. Calculate the sample concentration (IC) in the reaction solution when the ACE inhibition rate is 50%. 50 ).
[0060] The results are shown in Table 1.
[0061] The substrate solution was prepared by mixing 8 mM substrate (Hippuryl-His-Leu) (manufactured by Peptide Research Institute) and 640 mM sodium chloride in borate buffer (pH 8.3). The ACE solution was prepared by mixing 30 mU / mL ACE (manufactured by Sigma) in borate buffer.
[0062] 〈Liquid Chromatography Conditions〉
[0063] Column: Wakosil-II 5C18 HG (4.5 mm ID × 150 mm, manufactured by Wako Pure Chemical Industries, Ltd.)
[0064] Column temperature: 40°C
[0065] Mobile phase: 20 mM KH2PO4·H3PO4 (pH 3.0): methanol (57:43, v / v)
[0066] Flow rate: 1.0mL / min
[0067] Detection wavelength: 228nm
[0068] Injection volume: 20 μL
[0069] [Table 1]
[0070]
[0071] As shown in Table 1, it was confirmed that compound (I) (sample 1) had an excellent angiotensin converting enzyme inhibitory effect.
[0072] [Blending Example 1]
[0073] Tablets having the following composition were manufactured according to a conventional method.
[0074]
[0075] [Blending Example 2]
[0076] An oral liquid preparation having the following composition was prepared according to a conventional method.
[0077] <Ingredients in 1 ampoule (100 mL)>
[0078]
[0079] Industrial Availability
[0080] The angiotensin converting enzyme inhibitor and antihypertensive agent of the present invention can significantly contribute to the improvement of, for example, hypertension.
Claims
1. Use of a compound represented by the following formula (I) for the production of an angiotensin converting enzyme inhibitor, wherein the compound does not include the compound derived from rice or soybeans as a raw material of miso and remains in the miso, 2. Use of a compound represented by the following formula (I) for the manufacture of a hypotensive agent, wherein the compound does not include the compound derived from rice or soybeans as a raw material of miso and remaining in the miso, 3. Use of a compound represented by the following formula (I) for the manufacture of angiotensin converting enzyme inhibiting food or beverage, wherein the compound does not include the compound derived from rice or soybeans as a raw material of miso and remains in the miso, 4. Use of a compound represented by the following formula (I) for the manufacture of a blood pressure-lowering food or beverage, wherein the compound does not include the compound derived from rice or soybeans as a raw material of miso and remains in the miso,
